Nasopharyngeal carcinoma in children and young adults—Beyond 5‐year survival
Tal Ben Ami, Shifra Ash, Miri Ben‐Harosh, Herzel Gavriel, Michael Weintraub, Shoshana Revel‐Vilk, Myriam Ben‐Arush
Abstract
Nasopharyngeal carcinoma (NPC) is a rare and locally aggressive form of childhood cancer. Treatment of NPC includes chemotherapy and radiotherapy. With current treatment protocols, survival rates for patients with nonmetastatic disease is over 80%. Data regarding very late events including long-term treatment-related morbidities and second malignancies are scarce. We present our data on 42 patients with NPC treated in Israel between 1989 and 2014, and followed until 2019. During follow up, five patients had disease recurrence, and four children developed secondary malignancy. Median time to diagnosis of secondary malignancy was 105 months. Eighty-eight percent of patients have long-term treatment-related morbidities.